A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
BA-2664
Timepidium
The risk or severity of adverse effects can be increased when Revefenacin is combined with Timepidium.
BA-2664
Pipenzolate
The risk or severity of adverse effects can be increased when Revefenacin is combined with Pipenzolate.
BA-2664
Emetonium iodide
The risk or severity of adverse effects can be increased when Revefenacin is combined with Emetonium iodide.
BA-2664
Fenpiverinium
The risk or severity of adverse effects can be increased when Revefenacin is combined with Fenpiverinium.
BA-2664
Camylofin
The risk or severity of adverse effects can be increased when Revefenacin is combined with Camylofin.
BA-2664
Diphemanil
The risk or severity of adverse effects can be increased when Revefenacin is combined with Diphemanil.
BA-2664
Penthienate
The risk or severity of adverse effects can be increased when Revefenacin is combined with Penthienate.
BA-2664
Dihexyverine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Dihexyverine.
BA-2664
Tiemonium iodide
The risk or severity of adverse effects can be increased when Revefenacin is combined with Tiemonium iodide.
BA-2664
Etanautine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Etanautine.
BA-2664
Bornaprine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Bornaprine.
BA-2664
Rociverine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Rociverine.
BA-2664
Bevonium
The risk or severity of adverse effects can be increased when Revefenacin is combined with Bevonium.
BA-2664
Poldine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Poldine.
BA-2664
Otilonium
The risk or severity of adverse effects can be increased when Revefenacin is combined with Otilonium.
BA-2664
Etybenzatropine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Etybenzatropine.
BA-2664
Mazaticol
The risk or severity of adverse effects can be increased when Revefenacin is combined with Mazaticol.
BA-2664
Phenglutarimide
The risk or severity of adverse effects can be increased when Revefenacin is combined with Phenglutarimide.
BA-2664
Difemerine
The risk or severity of adverse effects can be increased when Revefenacin is combined with Difemerine.
BA-2664
Benzilone
The risk or severity of adverse effects can be increased when Revefenacin is combined with Benzilone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3